Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results tomorrow after market ...
After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...
Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the ...
Barclays analyst Luke Sergott lowered the firm’s price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm ...
Hosted on MSN20d
Life sciences stocks fall on NIH funding concernsPACB), also known as PacBio, both fell 10%, while Illumina (NASDAQ:ILMN) and Bio-Rad (BIO) shares fell 5% and 4%, respectively. Shares of Qiagen (QGEN) and Bruker (BRKR) slid 3%, with shares of ...
Rising demand for precision medicine & groundbreaking innovations in RNA sequencing drive growth in oncology, drug discovery, & personalized therapies. Akash Anand SNS Insider Pvt. Ltd 415-230-0044 ...
Illumina is estimated to have around 80% of the global DNA sequencing market, with Element one of a new generation of rivals alongside the likes of PacBio and Singular Genomics, which launched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback